Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • polsum
    Member
    • May 2009
    • 32

    Multiple Mappings

    Hi - I have shortRNA NGS data and there are many short reads that map to multiple types of microRNAs and some microRNAs and genes. To which type of microRNA or gene should I assign this read?

    For example if a read A maps to 4 different microRNAs mir-1, mir-2 mir-3 and mir-4, should I consider that read as mir-1 or 2 or 3 or 4? or should I equally distribute the mapping? like 25% to each?

    Please advice - thanks in advance.
  • polsum
    Member
    • May 2009
    • 32

    #2
    No one? I am pretty sure some of you might have encountered same question or problem. Thanks in advance.

    Comment

    • cjp
      Member
      • Jun 2011
      • 58

      #3
      I'm not exactly sure what you mean - but in this cufflinks help page:



      they say this for estimating FPKM values when a read maps to multiple places:

      "Individual reads will sometimes be mapped to multiple positions in the genome due to sequence repeats and homology. By default, Cufflinks will uniformly divide each multi-mapped read to all of the positions it maps to. In other words, a read mapping to 10 positions will count as 10% of a read at each position."

      Chris

      Comment

      • gringer
        David Eccles (gringer)
        • May 2011
        • 845

        #4
        Individual reads will sometimes be mapped to multiple positions in the genome due to sequence repeats and homology. By default, Cufflinks will uniformly divide each multi-mapped read to all of the positions it maps to. In other words, a read mapping to 10 positions will count as 10% of a read at each position.
        And if you read a little bit further:
        If multi-mapped read correction is enabled...Cufflinks will first calculate initial abundance estimates for all transcripts using the uniform dividing scheme. Cufflinks will then re-estimate the abundances dividing each multi-mapped read probabalistically based on the initial abundance estimation of the genes it maps to, the inferred fragment length, and fragment bias (if bias correction is enabled).

        Comment

        • polsum
          Member
          • May 2009
          • 32

          #5
          Thank you very much cjp, this is exactly what I am looking for.

          Comment

          Latest Articles

          Collapse

          • SEQadmin2
            Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
            by SEQadmin2


            Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

            The systematic characterization of the human proteome has
            ...
            07-20-2026, 11:48 AM
          • SEQadmin2
            Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
            by SEQadmin2



            Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
            ...
            07-09-2026, 11:10 AM
          • SEQadmin2
            Cancer Drug Resistance: The Lingering Barrier to Rising Survival
            by SEQadmin2



            Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

            There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
            07-08-2026, 05:17 AM

          ad_right_rmr

          Collapse

          News

          Collapse

          Topics Statistics Last Post
          Started by SEQadmin2, 07-20-2026, 11:10 AM
          0 responses
          14 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 07-13-2026, 10:26 AM
          0 responses
          32 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 07-09-2026, 10:04 AM
          0 responses
          43 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 07-08-2026, 10:08 AM
          0 responses
          29 views
          0 reactions
          Last Post SEQadmin2  
          Working...